Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
dc.contributor.author | Rasco, D | |
dc.contributor.author | Middleton, M | |
dc.contributor.author | Gonzalez, Rene | |
dc.contributor.author | Corrie, P | |
dc.contributor.author | Pavlick, A | |
dc.contributor.author | Lorigan, Paul C | |
dc.contributor.author | Plummer, R | |
dc.contributor.author | Gore, M | |
dc.contributor.author | Herbert, C | |
dc.contributor.author | Agarwala, S | |
dc.contributor.author | Logan, T | |
dc.contributor.author | Khleif, S | |
dc.contributor.author | Papadopoulos, K | |
dc.contributor.author | Rangachari, L | |
dc.contributor.author | Suri, A | |
dc.contributor.author | Xu, Q | |
dc.contributor.author | Kneissl, M | |
dc.contributor.author | Bozon, V | |
dc.contributor.author | Olszanski, A | |
dc.date.accessioned | 2016-01-06T10:08:13Z | en |
dc.date.available | 2016-01-06T10:08:13Z | en |
dc.date.issued | 2015 | en |
dc.identifier.citation | Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. 2015, 51 S53-S54 Eur J Cancer | en |
dc.identifier.uri | http://hdl.handle.net/10541/592919 | en |
dc.language.iso | en | en |
dc.title | Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma | en |
dc.title.alternative | Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | South Texas Accelerated Research Therapeutics START, Oncology,San Antonio, USA | en |
dc.identifier.journal | European Journal of Cancer | en |